Innovative Biomarker Platform Aushon BioSystems offers a highly cost-effective multiplex immunoassay platform with over 300 biomarkers, providing reliable and rapid protein biomarker data. This makes them an attractive partner for pharmaceutical and biotech companies seeking efficient research tools to accelerate drug discovery and development processes.

Recent Acquisition as Growth Indicator Being acquired by Quanterix Corporation in 2018 signifies recognition of Aushon's innovative technology and market potential, presenting opportunities for sales expansion through integrated product offerings and expanded reach within the life sciences and diagnostics sectors.

Focus on High-Sensitivity Assays The launch of ultra-sensitive assays like Ciraplex ULTRA reflects Aushon’s commitment to high-performance solutions, appealing to customers requiring the detection of low-abundance biomarkers for personalized medicine and advanced research applications.

Financial and Funding Momentum With revenue estimated between 1 million and 10 million and recent funding of nearly 6.8 million dollars, Aushon shows ongoing investment in innovation, creating opportunities to provide complementary products and services that align with their investment in high-sensitivity and multiplex technologies.

Niche Market Focus Aushon’s specialized focus on protein biomarker analysis for pharmaceutical, biotech, and academic clients positions it uniquely in the market, enabling tailored solutions and potential upselling opportunities with organizations engaged in cutting-edge biological research and personalized medicine initiatives.